Trials / Recruiting
RecruitingNCT05925452
To Evaluate the Efficacy and Safety of Genalumab for Injection in the Treatment of Active Systemic Juvenile Idiopathic Arthritis.
A Multicenter, Randomized Phase II/III Clinical Study to Evaluate the Efficacy and Safety of GenaKumab in the Treatment of Active Systemic Juvenile Idiopathic Arthritis.
- Status
- Recruiting
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 221 (estimated)
- Sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd. · Industry
- Sex
- All
- Age
- 2 Years – 17 Years
- Healthy volunteers
- Not accepted
Summary
A multicenter, randomized Phase II/III clinical study to evaluate the efficacy and safety of GenaKumab in the treatment of active systemic juvenile idiopathic arthritis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | GenaKumab | GenaKumab 3.0mg/kg dose group : GenaKumab 3.0 mg/kg, Subcutaneous injection, Q4w； GenaKumab 4.0 mg/kg dose group : GenaKumab 4.0 mg/kg, Subcutaneous injection, Q4w |
Timeline
- Start date
- 2023-12-01
- Primary completion
- 2028-03-24
- Completion
- 2028-06-29
- First posted
- 2023-06-29
- Last updated
- 2024-09-23
Locations
10 sites across 1 country: China
Source: ClinicalTrials.gov record NCT05925452. Inclusion in this directory is not an endorsement.